FDA advisory panel votes to back four research peptides

News summary. This describes a regulatory news event, reported from primary sources. It is not advice, and nothing here implies approval, a change in legal status, or any use in people. Products are supplied for laboratory research use only, not for human consumption.

On 23 July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding several research peptides to the 503A bulk drug substances list, a move reported to override written objections from the agency's own scientists.

What was voted on

Multiple outlets reported the panel backed BPC-157, KPV, TB-500 and MOTS-c, with the tallies covered as roughly 8 to 6 for BPC-157 and KPV, and 7 to 5 for MOTS-c.

What it does and does not mean

This is important to read carefully. The vote is a recommendation only, and non-binding. Commentators put the full rulemaking pathway at many months before compounding pharmacies would have any clear legal authority. In other words, this is a genuine news event and a signal of shifting attention toward these peptides, but no approval has happened and no legal status has changed.

Sources: STAT News, 23 July 2026, Pharmaceutical Executive, and the FDA meeting page

The four compounds

Each of the four sits in Revexa's research catalogue:

• BPC-157 10mg and BPC-157 5mg

• TB-500 10mg and TB-500 5mg

• KPV 10mg

• MOTS-c 10mg

All products at Revexa are supplied strictly for laboratory and research use only. Not for human or veterinary use, and not for consumption. This item reports a regulatory news event as published. The committee outcome is a non-binding recommendation and does not represent approval or a change in legal status.